Hologic Inc.
Hologic, Inc. Reports Annual Meeting Voting Results
Summary
Hologic, Inc. held its Annual Meeting of Stockholders on February 26, 2025, where all eight director nominees were elected, executive compensation was approved, Ernst & Young LLP was ratified as the independent auditor, and a stockholder proposal to change voting provisions was rejected. The meeting had a quorum of 93.38% of the outstanding shares. The election of directors saw widespread support, while the advisory vote on executive compensation and the ratification of the auditor also received majority approval. However, the stockholder proposal to replace supermajority voting with a simple majority standard was not approved.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement